目的分析研究伊立替康单药二线治疗进展期结直肠癌的临床价值。方法盲选本院收治的66例进展期结直肠癌患者,给予患者采用伊立替康单药二线治疗,分析评价其临床价值。结果 66例患者治疗后,部分缓解16例(24.2%),稳定34例(51.6%),进展16例(24.2%),有效率为24.2%,疾病控制率为75.8%。血液学毒性为Ⅰ度骨髓抑制以及Ⅱ度中性粒细胞减少症38例(57.6%),Ⅲ+Ⅳ度中性粒细胞减少症24例(36.4%);非血液学毒性为:Ⅰ+Ⅱ度恶心呕吐38例(57.6%),Ⅲ+Ⅳ度恶心呕吐5例(7.6%),Ⅰ+Ⅱ度迟发性腹泻24例(36.4%),Ⅲ+Ⅳ度迟发性腹泻4例(6.1%)。结论给予进展期结直肠癌患者采用伊立替康单药二线治疗,疗效满意,安全可靠,值得应用推广。 Objective To analyze the clinical value of irinotecan monotherapy second-line treatment of advanced colorectal cancer. Methods blind selection of 66 cases of patients with advanced colorectal cancer admitted to hospital with irinotecan monotherapy second-line treatment, analysis and evaluation of its clinical value. Results Sixty-six patients (24.2%) were relieved partially, 34 patients (51.6%) were stable and 16 patients (24.2%) were cured. The effective rate was 24.2% and the disease control rate was 75.8%. Hematological toxicity was grade Ⅰ myelosuppression and grade Ⅱ neutropenia in 38 cases (57.6%), grade Ⅲ + Ⅳ neutropenia in 24 cases (36.4%); non-hematological toxicity was: Ⅰ + Ⅱ (N = 37), nausea and vomiting in 38 cases (57.6%), grade Ⅲ + Ⅳ nausea and vomiting in 5 cases (7.6%), delayed diarrhea in 24 cases %). Conclusions The patients with advanced colorectal cancer were treated with irinotecan monotherapy second-line therapy, the results were satisfactory, safe and reliable, and should be applied and popularized.